Aevice Health Secures Patent Grant for AeviceMD in Japan—Strengthening Global IP Portfolio
- The AeviceMD has been granted a patent by the Japan Patent Office (JPO)
- The patent now protects AeviceMD’s proprietary system for continuous respiratory monitoring, supporting early detection of exacerbations and tracking of key vital signs such as heart and respiratory rate.
- Positions Aevice Health to accelerate partnerships and market access in Japan.
Singapore, 2 June 2025 – Aevice Health today announced that its flagship product, AeviceMD, has been officially granted a patent by the Japan Patent Office (JPO). This milestone strengthens the company’s global intellectual property portfolio and reinforces the originality of its Internet-of-Medical-Things (IoMT) respiratory care technology under Japanese patent law.
The patent covers AeviceMD’s proprietary solution for continuous respiratory monitoring, which supports the early detection of exacerbations, encourages medication adherence, and captures key vital signs such as heart rate and respiratory rate. Designed for both clinical and home use, the device provides clinicians with real-time, actionable insights to deliver more proactive and personalized care.
